ImmunoGen develops targeted anticancer therapeutics using expertise in cancer biology, engineered antibodies and highly potent cancer-cell killing agents.
US biotech firm ImmunoGen (Nasdaq: IMGN) develops targeted anticancer therapeutics using expertise in cancer biology, engineered antibodies and highly potent cancer-cell killing agents.
It has expertise in the development and humanization of tumor-targeting antibodies. Engineered antibodies can do an excellent job of selectively binding to cancer cells, but are typically sub-optimal in their ability to actually kill cancer cells. Immunogen has developed specialized cancer-cell killing agents to serve as payloads – to be attached to such antibodies for targeted delivery to tumor cells.
Its payload agents are many fold more potent than traditional chemotherapy agents. It has also developed engineered linkers that keep the payload firmly attached to the antibody while the whole therapy is circulating through the bloodstream and then release it once the therapy has reached and entered a cancer cell.
Immunogen also selectively outlicenses its technology to other companies for use with their engineered antibodies. It has partnerships with Amgen, Bayer, Biotest, Lilly, Novartis, Roche and Sanofi – all of which have clinical and/or preclinical compounds using its technology.
ImmunoGen is headquartered in Waltham, Massachusetts. Its manufacturing facility is in Norwood, Massachusetts. It has approximately 300 employees.